Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dimethaid WF10 fails Phase III for HIV

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Dimethaid is halting development of its HIV/AIDS agent WF10 following the immune regulator's failure to meet primary endpoints in a 96-week, placebo-controlled, double-blind Phase III trial. Results from the North American trial's 229 late-stage AIDS patients "indicated no statistical difference between WF10 and placebo in affecting the time to onset of clinical progression, defined as any new AIDS-defining event or death," the firm says July 14. Dimethaid plans to evaluate the study's secondary results and "re-evaluate WF10's future business potential and its position in the company's long-term development pipeline." The firm notes WF10 (tetrachlorodecaoxygen) may have potential in autoimmune diseases and oncology...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts